HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial

No abstract is available for this paper.

• Publication year

  2017

• Venue

  JAMA Oncology

• Publication date

  2017-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamaoncol.2017.0184PMID 28426845PMCID PMC5747970
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.

  2019cited by this paper
• Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

  2016cited by this paper
• Tetanus toxoid and CCL3 improve DC vaccines in mice and glioblastoma patients

  2015cited by this paper
• T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

  2015cited by this paper
• Transforming growth factor-beta and its implication in the malignancy of gliomas

  2015cited by this paper
• Immunotherapy for malignant glioma

  2015cited by this paper
• Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.

  2015cited by this paper
• Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients

  2015cited by this paper
• Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.

  2015cited by this paper
• Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.

  2015cited by this paper
• Prospects of immune checkpoint modulators in the treatment of glioblastoma

  2015cited by this paper
• Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma

  2015cited by this paper
• Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

  2015cited by this paper
• Chimeric antigen receptor T cells for sustained remissions in leukemia.

  2014cited by this paper
• World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

  2014cited by this paper
• Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

  2014cited by this paper
• Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma.

  2014cited by this paper
• Post progression survival in glioblastoma: where are we?

  2014cited by this paper
• Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas.

  2014cited by this paper
• World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

  2013cited by this paper
• EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss

  2013cited by this paper
• Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.

  2013cited by this paper
• Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma

  2013cited by this paper
• T cells redirected to EphA2 for the immunotherapy of glioblastoma.

  2013cited by this paper
• Generation of Polyclonal CMV-specific T Cells for the Adoptive Immunotherapy of Glioblastoma

  2012cited by this paper
• Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group.

  2011cited by this paper
• Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

  2010cited by this paper
• Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

  2010cited by this paper
• HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors

  2010influential reference
• Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

  2010cited by this paper
• Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma

  2010cited by this paper
• Successful Treatment of Melanoma Brain Metastases with Adoptive Cell Therapy

  2010cited by this paper
• Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.

  2009cited by this paper
• Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

  2008cited by this paper
• Regression of experimental medulloblastoma following transfer of HER2-specific T cells.

  2007cited by this paper
• Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals

  2006influential reference
• Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.

  2005cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper

• Characterizing renal complications in immune effector cell therapies in pediatric hematological and solid tumors

  2026cites this paper
• Mathematical modeling of combinatorial antigen targeting with multiple CAR T-cell products for glioblastoma treatment

  2026cites this paper
• Immunotherapies for Central Nervous System Tumors and their Neurologic Complications

  2026influential citation
• Cell therapy for brain tumors: The first 60 years.

  2026cites this paper
• The immune awakening: Transformative strategies against brain tumors.

  2026cites this paper
• CAR-T cell therapies are coming after glioblastoma: An overview of early phase clinical trials and future perspectives

  2026cites this paper
• Current state of CAR-T cell therapies for solid tumors.

  2026cites this paper
• KRASG12V/HLA-A*02:01-targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors.

  2026cites this paper
• CAR-T cell therapy for pediatric high grade gliomas: Opportunities, challenges, and future directions

  2026cites this paper
• GITR activation potentiates anti-tumor immunity of tumor-infiltrating lymphocytes expanded from glioblastoma by rescuing exhaustion.

  2026cites this paper
• CAR-T Cell Therapy in Glioblastoma: Overcoming Immunological Barriers and Advancing Clinical Translation.

  2026cites this paper
• Recurrent Glioblastoma and the Tumor Immune Landscape: Emerging Immunotherapeutic Strategies

  2026cites this paper
• The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.

  2026cites this paper
• Efficacy, safety and cost-effectiveness of CAR-T therapy.

  2026cites this paper
• Advancements in Drug Delivery Systems in Glioblastoma Therapy

  2026cites this paper
• Ligand-based CAR design enhances durability of CD70-targeted CAR T cells in glioblastoma.

  2026cites this paper
• Immunotherapy and targeted therapy for high grade gliomas: current and future directions

  2025cites this paper
• Advances and challenges in CAR-T therapy for glioblastoma.

  2025cites this paper
• Study on the anti-tumor effect of PDL1-CAR-γδT cells constructed with nanobody sequences on glioblastoma.

  2025cites this paper
• Current Role of CAR-T Therapy in Haematological Care.

  2025cites this paper
• Translational advancement of immunotherapeutics against pediatric central nervous system tumors.

  2025cites this paper
• Glioblastoma insights: Focus on crosstalk with the suppressive tumor microenvironment and advanced therapeutic strategies

  2025cites this paper
• Challenges and Opportunities in High-Grade Glioma Management and Imaging-Based Response Monitoring During Novel Immunotherapies

  2025cites this paper
• Small-molecule therapies targeting tumor-associated macrophages in glioma: mechanisms and potential.

  2025cites this paper
• Application Value and Research Frontiers of Immunotherapy in Glioblastoma: A Bibliometric and Visualized Analysis

  2025cites this paper
• The development of CAR T cells for patients with CNS malignancies

  2025cites this paper
• Emerging therapies for glioblastoma

  2025cites this paper
• Synergy of radiotherapy, focused ultrasound, and immunotherapy in the treatment of brain metastases

  2025cites this paper
• Immunotherapy for precision medicine in colorectal cancer

  2025cites this paper
• Advances in neuroscientific mechanisms and therapies for glioblastoma

  2025cites this paper
• Integrative Multi-Omics Features Stratify Metabolic and Immune Subtypes in Glioma.

  2025cites this paper
• Generation of patient-derived sarcoma organoids for personalized drug screening and precision cancer immunotherapy.

  2025cites this paper
• Combining immunotherapy with radiotherapy for glioblastoma: recent advances and challenges

  2025cites this paper
• Status and Prospects of Glioblastoma Multiforme Treatments

  2025cites this paper
• Engineering adoptive cell therapy for solid tumors

  2025influential citation
• Chimeric antigen receptor NK-92 cell function is modulated by HLA class I expression of target cells

  2025cites this paper
• Antitumor Activities by a Humanized Cancer‐Specific Anti‐Podoplanin Monoclonal Antibody humPMab‐117 Against Human Tumors

  2025influential citation
• Evolving CAR T-Cell Therapy to Overcome the Barriers in Treating Pediatric Central Nervous System Tumors.

  2025cites this paper
• Unraveling the immunosuppressive microenvironment of glioblastoma and advancements in treatment

  2025cites this paper
• Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors

  2025cites this paper
• Emerging Chemotherapy Targets: Insights from Advances in Glioma Treatment

  2025cites this paper
• NRCAM variant defined by microexon skipping is a targetable cell surface proteoform in high-grade gliomas

  2025cites this paper
• Immunotherapy in Glioblastoma: An Overview of Current Status

  2025cites this paper
• Optimised modular anti‐FLAG CAR T cells for solid tumor therapy

  2025cites this paper
• Genetic Engineering in CAR T Cells for Solid Tumors: Current State, Barriers and Future Developments

  2025cites this paper
• Enhancing T cell infiltration in glioblastoma: a review article on challenges and therapeutic strategies.

  2025cites this paper
• HER2-CAR-NK cells exhibit enhanced cytotoxic activity towards HER2-positive tumors

  2025cites this paper
• Enhanced FOS expression improves tumor clearance and resists exhaustion in NR4A3-deficient CAR T cells under chronic antigen exposure

  2025cites this paper
• Biology of stem cell paradox: a double-edged sword-implications for cancer therapy

  2025cites this paper
• Advancing Glioblastoma Treatment: The Emerging Role of CAR-T Cell Therapy

  2025cites this paper
• Preclinical development and selection of nanobody-based CAR-T cells targeting HER2-positive solid tumors

  2025cites this paper
• Lysosome‐Mediated Targeted Protein Degradation: Emerging Chimeric Platforms for Extracellular and Intracellular Therapeutics

  2025cites this paper
• Chimeric Antigen Receptor-Based Cellular Therapy for T-Cell Malignancies.

  2025cites this paper
• Recurrent Limitations of CAR-T Therapy in Gliomas: Evidence from Preclinical and Phase I Clinical Studies

  2025influential citation
• Therapeutic Targets in Glioblastoma: Molecular Pathways, Emerging Strategies, and Future Directions

  2025cites this paper
• Unravelling the modified T cell receptor through Gen-Next CAR T cell therapy in Glioblastoma: Current status and future challenges.

  2025cites this paper
• Gene and Cell Therapy for Sarcomas: A Review

  2025cites this paper
• From Brain Scans to Therapy Response: PDE Modelling of Immunotherapy for Glioblastoma

  2025cites this paper
• An update on the clinical trial research of immunotherapy for glioblastoma

  2025cites this paper
• A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function

  2025cites this paper
• In Vivo Ultrasound and Photoacoustic Imaging of Nanoparticle-Engineered T Cells and Post-Treatment Assessment to Guide Adoptive Cell Immunotherapy

  2025cites this paper
• Cellular Kinetics and Biodistribution of Adoptive T Cell Therapies: from Biological Principles to Effects on Patient Outcomes

  2025cites this paper
• Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral context

  2025cites this paper
• Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture

  2025cites this paper
• Cardiovascular Complications of Immune Effector Cell Therapies in Pediatric Hematological and Solid Tumors

  2025cites this paper
• Advancements in targeted and immunotherapy strategies for glioma: toward precision treatment

  2025cites this paper
• CAR T cells, CAR NK cells, and CAR macrophages exhibit distinct traits in glioma models but are similarly enhanced when combined with cytokines

  2025cites this paper
• Chimeric Antigen Receptor Cells Solid Tumor Immunotherapy Assisted by Biomaterials Tools.

  2025cites this paper
• Challenges and Emerging Strategies of Immunotherapy for Glioblastoma

  2025cites this paper
• The development and potent antitumor efficacy of CD44/CD133 dual-targeting IL7Rα-armored CAR-T cells against glioblastoma.

  2025cites this paper
• CAR T Cell Therapy for Glioblastoma: A Review of the First Decade of Clinical Trials.

  2025cites this paper
• CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma

  2025cites this paper
• Tonic signaling in CAR-T therapy: the lever long enough to move the planet

  2025cites this paper
• Integrative multi-omic profiling of the neoantigen landscape of glioblastoma for the development of therapeutic vaccines reveals vast heterogeneity in immunogenic signatures

  2025cites this paper
• Strategies for Altering Delivery Technologies to Optimize CAR Therapy

  2025cites this paper
• Glioblastoma Stem Cells at the Nexus of Tumor Heterogeneity, Immune Evasion, and Therapeutic Resistance

  2025cites this paper
• Cell therapies against brain tumors: Clinical development and emerging prospects

  2025influential citation
• Immuntherapie gegen Gliome - wie ist der Status quo?

  2025cites this paper
• Optimal fractionation scheme for lymphocyte infiltration in glioblastoma multiforme radiotherapy

  2025cites this paper
• Glioblastoma: molecular features, emerging molecular targets and novel therapeutic strategies.

  2025cites this paper
• Effectiveness, Limitations, and Future Perspectives of CAR-T Cell Therapy in Solid Tumor Treatment: A Narrative Review

  2025cites this paper
• Universal Dual-Target CAR-γδT Cells Targeting B7-H3 and IL13Rα2 for Glioblastoma Therapy

  2025cites this paper
• Chimeric antigen receptor (CAR)-T-cell therapy for glioblastoma: what can we learn from the early clinical trials? A systematic review

  2025cites this paper
• A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial

  2025cites this paper
• Adoptive cell therapy with macrophage-drug conjugates facilitates cytotoxic drug transfer and immune activation in glioblastoma models.

  2025cites this paper
• A Critical Review of CAR-T Therapies for Glioblastoma: What's Wrong with the Current Attempts?

  2025cites this paper
• CAR-T cell therapy for glioblastoma: advances, challenges, and future directions

  2025influential citation
• Neuroimmunology-driven CAR T-cell therapeutics for gliomas: translational challenges and clinical trial paradigm innovation.

  2025cites this paper
• Glioblastoma: From Pathophysiology to Novel Therapeutic Approaches

  2025influential citation
• Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: Interim clinical experience demonstrating feasibility and safety

  2025cites this paper
• CAR T cell therapy for central nervous system solid tumors: current progress and future directions

  2025cites this paper
• Preclinical efficacy of multi-targeting mRNA-based CAR T cell therapy in resection models of glioblastoma

  2025cites this paper
• Expanding Immunotherapy Beyond CAR T Cells: Engineering Diverse Immune Cells to Target Solid Tumors

  2025cites this paper
• Cellular immunotherapies for central nervous system cancers

  2025cites this paper
• A first evaluation of the efficacy of minibeam radiation therapy combined with an immune check point inhibitor in a model of glioma-bearing rats

  2025cites this paper
• CAR-T in relapsed refractory high-grade glioma and glioblastoma – who, what, when and how?

  2025cites this paper
• GPC2-CAR T cells have potent preclinical activity against orthotopic medulloblastoma xenografts

  2025cites this paper
• The promise of immunotherapy for central nervous system tumours

  2025cites this paper
• The microenvironment of glioblastoma: in pursuit of universal multimodal immunotherapy.

  2025cites this paper
• Hunting glioblastoma recurrence: glioma stem cells as retrospective targets.

  2025cites this paper